Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
16 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) | belinostat
Show Display Options
Rank Status Study
1 Completed Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: PXD101
2 Completed Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Conditions: Solid Tumor;   Lymphoma
Intervention: Drug: oral belinostat
3 Completed
Has Results
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Conditions: Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma
Intervention: Drug: belinostat
4 Completed Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Belinostat;   Drug: CHOP
5 Not yet recruiting Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Conditions: Relapsed and Refractory Aggressive B- and T-cell Lymphomas;   Lymphoma
Interventions: Drug: volasertib;   Drug: belinostat
6 Recruiting Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Conditions: Neoplasms;   Lymphomas
Intervention: Drug: Belinostat
7 Withdrawn Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
Condition: Lymphoma
Interventions: Drug: Busulfan;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Drug: Belinostat;   Drug: Azacitidine;   Drug: Gemcitabine;   Drug: Melphalan;   Procedure: Stem Cell Transplant
8 Withdrawn A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Belinostat;   Drug: Rituximab;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Ciprofloxacin;   Drug: Fluconazole
9 Recruiting Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
Conditions: Adult T-cell Leukemia-Lymphoma;   ATLL
Interventions: Drug: Belinostat;   Drug: Zidovudine;   Drug: Interferon-Alfa-2b;   Drug: Pegylated Interferon-Alfa-2b
10 Active, not recruiting Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: belinostat;   Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
11 Terminated
Has Results
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Conditions: Cutaneous T-Cell Lymphoma;   Peripheral T-Cell Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: belinostat
12 Recruiting Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
Conditions: Non-Hodgkin Lymphoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Belinostat
13 Completed PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: belinostat;   Drug: bortezomib;   Other: pharmacological study
14 Terminated PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: tanespimycin;   Drug: belinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Completed Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Conditions: Accelerated Phase of Disease;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Disease;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Belinostat;   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis
16 Completed Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphocytic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib;   Drug: belinostat;   Other: laboratory biomarker analysis;   Genetic: western blotting;   Other: pharmacological study;   Other: flow cytometry

Study has passed its completion date and status has not been verified in more than two years.